Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
Gilead Sciences Inc. closed $4.71 below its 52-week high ($87.87), which the company achieved on January 19th.
Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, ...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...
Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...
The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback